CARLSBAD, Calif., Jan. 29, 2019 /PRNewswire/ -- Qualigen, Inc., a privately-owned company that provides novel diagnosticand therapeutic technologies for the treatment of cancer and infectious diseases, today announced that the Company has received clearance from the U.S. Food and Drug Administration for its FastPack IP Sex Hormone Binding Globulin (SHBG) Immunoassay.
About Qualigen, Inc.Qualigen, Inc. is a medical device company focused on the development, production and commercialization of innovative medical technologies, including its flagship FastPack® point-of-care immunoassay system and novel therapeutic technologies for treatment of cancers and infectious diseases. For more information, visit www.qualigeninc.com.
© 2019 Qualigen. All rights reserved. Qualigen, the stylized logo, and FastPack are registered trademarks of Qualigen, Incorporated in the United States and other countries.
View original content:http://www.prnewswire.com/news-releases/qualigen-receives-fda-clearance-for-its-fastpack-ip-shbg-assay-300786371.html
SOURCE Qualigen, Inc.
Subscribe to our Free Newsletters!